ReviewNature reviews. Cancer2009
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.
Review in Nature reviews. Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 1 synthesis or guideline pooled it, 292 citations in OpenAlex.
- Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma.Gastroenterology · 2020Pooled it
- A Common CD36 Variant Influences Endothelial Function and Response to Treatment with Phosphodiesterase 5 Inhibition.The Journal of clinical endocrinology and metabolism · 2016Trial
- Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation.Molecular medicine (Cambridge, Mass.) · 2026Review
- Irisin Signaling Resistance in Myalgic Encephalomyelitis: A Proposed Mechanistic Framework for Post-Exertional Malaise Involving the TSP-1-HSP90α-αvβ5 Axis.International journal of molecular sciences · 2026Article
- THBS1: a biomarker for PCOS and its role in pathogenesis via the PI3K/AKT signaling pathway.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Machine learning integrated clinical-proteomics data identifies a 6-protein panel signature for atherosclerotic severity and enhanced patient stratification.Molecular biomedicine · 2026Article
- Co-delivery of synaptogenic and angiogenic nanoparticles in MAP scaffolds enhances post-stroke synapse formation.Journal of materials chemistry. B · 2026Article
- Suppression of distal-less homeobox 3 increased alveolar bone mass in mouse tooth socket by targeting thrombospondin 1.Journal of dental sciences · 2026Article
- The role of thrombospondin-1 in dermatological conditions.Frontiers in medicine · 2026Review
- Mapping the complexity of ME/CFS: Evidence for abnormal energy metabolism, altered immune profile, and vascular dysfunction.Cell reports. Medicine · 2025Article
- CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion.Acta biochimica et biophysica Sinica · 2025Review
- Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis.Lupus science & medicine · 2025Article
- Tumor-specific liquid metal nitric oxide nanogenerator for enhanced breast cancer therapy.Asian journal of pharmaceutical sciences · 2025Article
- Mechanism of THBS1 Regulation of MDCK Cell Proliferation and Apoptosis Through TGF-β/Smad Signalling.International journal of molecular sciences · 2025Article
- Smoking and endometriosis: A narrative review.Tobacco induced diseases · 2025Review
- CD47 signaling induces hepatic cell death and microglia activation during hepatic encephalopathy.Metabolic brain disease · 2024Article
- Article
- PP2A Affects Angiogenesis via Its Interaction with a Novel Phosphorylation Site of TSP1.International journal of molecular sciences · 2024Article
- Mir-338-3p targeting THBS1 attenuates glioma progression by inhibiting the PI3K/Akt pathway.Biology direct · 2024Article
- The Role of Amino Acids in Non-Enzymatic Antioxidant Mechanisms in Cancer: A Review.Metabolites · 2023Review
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
In addition to long-term regulation of angiogenesis, angiogenic growth factor signalling through nitric oxide (NO) acutely controls blood flow and haemostasis. Inhibition of this pathway may account for the hypertensive and pro-thrombotic side effects of the vascular endothelial growth factor antagonists that are currently used for cancer treatment. The first identified endogenous angiogenesis inhibitor, thrombospondin 1, also controls tissue perfusion, haemostasis and radiosensitivity by antagonizing NO signalling. We examine the role of these and other emerging activities of thrombospondin 1 in cancer. Clarifying how endogenous and therapeutic angiogenesis inhibitors regulate vascular NO signalling could facilitate development of more selective inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.